Jean Jacques Bienaime - Apr 29, 2022 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Chief Executive Officer, Director
Signature
/s/ Laura Randall Woodhead, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Apr 29, 2022
Transactions value $
-$1,316,319
Form type
4
Date filed
5/9/2022, 09:29 PM
Previous filing
May 2, 2022
Next filing
Jun 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $21.3K +341 +0.1% $62.41 335K Apr 29, 2022 Direct F1
transaction BMRN Common Stock Options Exercise $375K +10K +2.98% $37.46 345K May 5, 2022 Direct F2
transaction BMRN Common Stock Sale -$841K -10K -2.9% $84.14 335K May 5, 2022 Direct F2
transaction BMRN Common Stock Options Exercise $749K +20K +5.96% $37.46 355K May 6, 2022 Direct F3
transaction BMRN Common Stock Sale -$1.62M -20K -5.63% $81.00 335K May 6, 2022 Direct F3
holding BMRN Common Stock 248K Apr 29, 2022 Shares held by Jean-Jacques Bienaime Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -10K -33.33% $0.00 20K May 5, 2022 Common Stock 10K $37.46 Direct F2, F4
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -20K -100% $0.00* 0 May 6, 2022 Common Stock 20K $37.46 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired by the reporting person on April 29, 2022, pursuant to the issuer's Employee Stock Purchase Plan.
F2 Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022.
F3 Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. Mr. Bienaime's former spouse will receive approximately 73% of the net proceeds from the shares sold in this transaction pursuant to a marital separation agreement between her and Mr. Bienaime.
F4 Reflects the number of options outstanding after the transactions from this specific stock option grant.